SCHEMBL3376912

SCHEMBL3376912

COc1ccc(C=O)c(OCOC(C)OC)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.58
TRIM24 O15164 1/20 0.45
TYR P14679 1/20 0.45
TRIM33 Q9UPN9 1/20 0.45
HDAC8 Q9BY41 2/20 0.43
ERN1 O75460 2/20 0.42
CYP1A2 P05177 4/20 0.41
CYP1A1 P04798 3/20 0.41
CYP1B1 Q16678 3/20 0.41
KDM4E B2RXH2 2/20 0.40
MAPT P10636 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
RAB9A P51151 1/20 0.40
LMNA P02545 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
MAOB P27338 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4998800 0.93 ALDH1A1 (0.47) ALDH1A1TRIM24TYRTRIM33HDAC8
SCHEMBL5566174 0.82 ALDH1A1 (0.80) ALDH1A1TRIM24TYRTRIM33ERN1
SCHEMBL3209556 0.82 ALDH1A1 (0.69) ALDH1A1TRIM24TYRTRIM33HDAC8
SCHEMBL640294 0.80 ALDH1A1 (0.56) ALDH1A1ERN1CYP1A2KDM4EMAPT
SCHEMBL3378064 0.78 BCHE (0.43) ALDH1A1TYRERN1KDM4EMAPT
SCHEMBL8447028 0.77 ALDH1A1 (0.71) ALDH1A1TRIM24TYRTRIM33HDAC8
SCHEMBL1748666 0.77 ALDH1A1 (0.71) ALDH1A1TRIM24TYRTRIM33HDAC8
SCHEMBL3924348 0.77 ALDH1A1 (0.71) ALDH1A1TRIM24TYRTRIM33ERN1
SCHEMBL3376914 0.76 ALDH1A1 (0.59) ALDH1A1TRIM24TYRTRIM33HDAC8
SCHEMBL96291 0.75 ALDH1A1 (1.00) ALDH1A1TRIM24TYRTRIM33ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1796665-B1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS MERCK SHARP & DOHME (US) 2010-11-17 EP disclosed
US-7629372-B2 Compounds for the treatment of dyslipidemia and other lipid disorders MERCK & CO., INC. (US) 2009-12-08 US disclosed
EP-1796665-A4 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS MERCK & CO INC (US) 2009-08-12 EP disclosed
US-20080039514-A1 Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders MERCK & CO., INC. (US) 2008-02-14 US disclosed
EP-1796665-A2 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS Merck & Co., Inc. (US) 2007-06-20 EP disclosed
WO-2006033891-A2 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS MERCK & CO., INC. (US) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039514-A1 Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders LIPA, APOB, LCAT ALDH1A1 660/4885TRIM24 4398/4885TYR 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.